Bizjak Nina, Bajd Franci, Vidmar Jernej, Blinc Aleš, Perme Maja Pohar, Marder Victor J, Novokhatny Valery, Serša Igor
Jožef Stefan Institute, Ljubljana, Slovenia.
Institute of Physiology, Medical Faculty of Ljubljana, Slovenia.
Thromb Res. 2014 May;133(5):908-13. doi: 10.1016/j.thromres.2014.02.008. Epub 2014 Feb 22.
Plasmin is a direct-acting thrombolytic agent with a favorable safety profile upon intra-arterial delivery in pre-clinical and phase I studies. However, the thrombolytic efficacy of plasmin, relative to that of rt-PA, remains to be established. We have compared the dynamics of clot lysis with plasmin or rt-PA in an in vitro perfusion system, in which thrombolytic agent is administered locally, allowed to induce lysis for short intervals, then washed with plasma in a re-circulation circuit.
Whole blood human clots were prepared in observation chambers, exposed to plasmin or rt-PA at equimolar concentrations (1.2/1.0, 1.8/1.5 and 2.4/2.0 mg/ml) for measured intervals of time, followed by perfusion with human plasma. Clot size was monitored by digital analysis of sequential photographs obtained through an optical microscope.
Plasma perfusion after incubation with thrombolytic agent rapidly removed superficial clot fragments. This initial decrease in clot size was greater with plasmin than with rt-PA when tested at the highest concentrations of agent (0.63 ± 0.11 vs. 0.30 ± 0.11, p=0.001 for clots with non-cross-linked fibrin and 0.53 ± 0.15 vs. 0.14 ± 0.15, p=0.02, for clots with cross-linked-fibrin). Subsequent clot lysis during plasma flow was greater after prior incubation with rt-PA. Longer incubation times of plasmin resulted in larger portions of the clot being washed free. Repeated plasmin incubations and plasma perfusions of a clot successfully induced stepwise reductions in clot size.
Initial clot lysis is greater with direct exposure using plasmin than rt-PA. During washout and circulation with plasma, rt-PA induced continued clot lysis, while plasmin lysis was curtailed, presumably because of plasmin inhibition.
纤溶酶是一种直接作用的溶栓剂,在临床前和I期研究中经动脉内给药时具有良好的安全性。然而,相对于重组组织型纤溶酶原激活剂(rt-PA),纤溶酶的溶栓效果仍有待确定。我们在体外灌注系统中比较了纤溶酶或rt-PA的凝块溶解动力学,在该系统中,溶栓剂局部给药,短时间诱导溶解,然后在再循环回路中用血浆冲洗。
在观察室中制备全血人凝块,在等摩尔浓度(1.2/1.0、1.8/1.5和2.4/2.0mg/ml)下暴露于纤溶酶或rt-PA一段测量时间,然后用人血浆灌注。通过光学显微镜获得的连续照片的数字分析监测凝块大小。
用溶栓剂孵育后进行血浆灌注可迅速去除表面凝块碎片。在最高浓度的药物测试中,纤溶酶处理时凝块大小的初始减小比rt-PA更大(对于非交联纤维蛋白凝块,分别为0.63±0.11和0.30±0.11,p = 0.001;对于交联纤维蛋白凝块,分别为0.53±0.15和0.14±0.15,p = 0.02)。在血浆流动期间,先前用rt-PA孵育后凝块溶解更大。纤溶酶孵育时间越长,被冲洗掉的凝块部分越大。对凝块重复进行纤溶酶孵育和血浆灌注成功诱导凝块大小逐步减小。
直接使用纤溶酶暴露时的初始凝块溶解比rt-PA更大。在血浆冲洗和循环期间,rt-PA诱导持续的凝块溶解,而纤溶酶溶解受到抑制,推测是由于纤溶酶抑制。